Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294
completedphase_1

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

NCT01899053
terminatedphase_1

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02393209
completedphase_1

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

NCT02625259
completedphase_1

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

NCT01449370

Clinical Trials (5)

Showing 5 of 5 trials
NCT03154294Phase 1

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Completed
NCT01899053Phase 1

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Completed
NCT02393209Phase 1

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Terminated
NCT02625259Phase 1

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Completed
NCT01449370Phase 1

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5